Mesa Laboratories, Inc. reported a revenue increase of 3.4% for the fiscal year ending March 31, 2026, totaling $249.1 million, compared to $241.0 million in the previous fiscal year. The company achieved a net income of $6.7 million, a significant recovery from a net loss of $2.0 million in fiscal 2025. This improvement in profitability was attributed to enhanced operational efficiencies and a favorable geographic revenue mix, particularly in the Clinical Genomics division, despite challenges in the market.
The company experienced notable growth in its Sterilization and Disinfection Control division, which saw revenues rise by 8.7% to $101.6 million, driven by price increases and a favorable currency impact. The Calibration Solutions division also contributed positively, with a revenue increase of 3.5% to $53.6 million. However, the Clinical Genomics division faced a revenue decline of 3.6% to $45.4 million, primarily due to reduced demand in China amid ongoing trade tensions and macroeconomic uncertainties. The Biopharmaceutical Development division remained stable, with revenues of $48.6 million, reflecting a slight decrease of 0.2%.
Mesa Laboratories made strategic advancements during the fiscal year, including the acquisition of GKE GmbH and SAL GmbH, which expanded its product offerings in the Sterilization and Disinfection Control division. The total consideration for the acquisition was approximately $87.2 million, which was funded through cash and borrowings under its credit facility. The integration of GKE is expected to enhance Mesa's capabilities in chemical sterilization indicators and broaden its market reach in Europe and Asia.
Operationally, the company maintained a workforce of 717 employees as of March 31, 2026, with no increase in headcount despite higher revenues. The company reported a decrease in voluntary employee turnover, indicating improved employee retention. Mesa Laboratories also noted a backlog of approximately $33.6 million, down from $43.2 million in the previous year, attributed to the timing of order placements and fulfillments, particularly in the Clinical Genomics division.
Looking ahead, Mesa Laboratories anticipates continued challenges in the Clinical Genomics division due to external market conditions, particularly in China. However, the company expects the financial impact of these challenges to be less severe in fiscal year 2027. The management remains focused on organic growth through customer base expansion and product offerings while leveraging operational efficiencies to enhance profitability.
About MESA LABORATORIES INC /CO/
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated industries such as pharmaceuticals, healthcare, and medical devices. Its core segments include sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company provides products and services that ensure product integrity, safety, and regulatory compliance, serving global markets through direct sales and distribution channels.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.